Home › Nexvet And Zenoaq Announce PD-1 mAb Candidate For Canine Cancer
 

Keywords :   


Nexvet And Zenoaq Announce PD-1 mAb Candidate For Canine Cancer

2016-05-03 02:58:08| drugdiscoveryonline Home Page

Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, and Zenoaq (Nippon Zenyaku Kogyo Co., Ltd.), a leading Japanese animal health company, announced today their research and development collaboration has yielded fully caninized, or ‘100% dog’, monoclonal antibodies (mAbs) that bind and potently inhibit the immuno-oncology target programmed cell death protein 1 (PD-1).

Tags: cancer candidate announce canine

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05We Recycle Solar Expands Partnership with Renewables.org
20.05Washington State Authorizes Drone for Methane Emissions
20.05The Heart, Science & Business of Sustainability: A Fireside Chat with Tara Hemmer
20.05Commissioners Celebrate the Opening of New Waste Transfer Station in Redmond, Ore.
20.05Newhaven Food Waste Facility Plans Paused Following Residents Concerns
20.05Business Report May 2024Highlights from WasteExpo 2024
More »